Superblood: The Development of Novel Red-Cell Therapeutics
16 dic 2017 ·
33 min. 27 sec.
Iscriviti gratuitamente
Ascolta questo episodio e molti altri. Goditi i migliori podcast su Spreaker!
Scarica e ascolta ovunque
Scarica i tuoi episodi preferiti e goditi l'ascolto, ovunque tu sia! Iscriviti o accedi ora per ascoltare offline.
Descrizione
In this episode of The Onco'Zine Brief, Peter Hofland and Sonia Portillo, talk with David R. Epstein B.Sc, MBA, the Executive Chairman of Rubius Therapeutics. Epstein explains how his company...
mostra di più
In this episode of The Onco'Zine Brief, Peter Hofland and Sonia Portillo, talk with David R. Epstein B.Sc, MBA, the Executive Chairman of Rubius Therapeutics.
Epstein explains how his company is pioneering novel Red-Cell Therapeutics or RCTs – nicknamed ‘superblood’ – as a new class of medicines to address a wide array of diseases.
He explains how these novel drugs have leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
mostra meno
Epstein explains how his company is pioneering novel Red-Cell Therapeutics or RCTs – nicknamed ‘superblood’ – as a new class of medicines to address a wide array of diseases.
He explains how these novel drugs have leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
Informazioni
| Autore | Peter Hofland |
| Sito | - |
| Tag |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
